Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LYN | P07948 | 2/20 | 0.30 |
| ▸ | SRC | P12931 | 2/20 | 0.30 |
| ▸ | BTK | Q06187 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4365173 | 0.89 | SMN1; SMN2 (0.39) | SMN1; SMN2MAPK14ALDH1A1 | |
| SCHEMBL4365170 | 0.88 | ALDH1A1 (0.33) | MAPK14CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL4371300 | 0.87 | ADORA2A (0.33) | SMN1; SMN2MAPK14CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL8102952 | 0.86 | ADORA2A (0.33) | SMN1; SMN2MAPK14CHRM2CHRM4CHRM5 | |
| SCHEMBL4361494 | 0.83 | MAOA (0.38) | ALDH1A1ADORA2AADORA1L3MBTL1 | |
| SCHEMBL29805708 | 0.83 | MAOA (0.38) | ALDH1A1ADORA2AADORA1L3MBTL1 | |
| SCHEMBL4582236 | 0.82 | CDYL (0.35) | SMN1; SMN2ALDH1A1KMT2AKDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL7427191 | 0.81 | CDYL (0.35) | SMN1; SMN2ALDH1A1KMT2AKDM4EMEN1 | |
| SCHEMBL3028481 | 0.79 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL14311499 | 0.79 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1736468-A2 | Isatin derivatives with neurotrophic activity useful in the treatment of diseases mediated by the nerve growth factor (NGF) activation | NeuroSearch A/S (DK) | 2006-12-27 | — | — | EP | claimed |
| US-20060229311-A1 | Isatine derivatives with neurotrophic activity | GROENBORG METTE | 2006-10-12 | — | — | US | claimed |
| JP-2003520851-A | — | — | 2003-07-08 | — | — | JP | claimed |
| US-20030040518-A1 | Isatine derivatives with neurotrophic activity | ANIONA APS (DK) | 2003-02-27 | — | — | US | claimed |
| EP-1255734-A1 | ISATINE DERIVATIVES WITH NEUROTROPHIC ACTIVITY | NeuroSearch A/S (DK) | 2002-11-13 | — | — | EP | claimed |
| WO-2001055110-A1 | ISATINE DERIVATIVES WITH NEUROTROPHIC ACTIVITY | NEUROSEARCH A/S (DK) | 2001-08-02 | — | — | WO | claimed |
| US-7595336-B2 | Isatine derivatives with neurotrophic activity | NEUROSEARCH A/S (DK) | 2009-09-29 | — | — | US | disclosed |
| US-7282511-B2 | Isatine derivatives with neurotrophic activity | NEUROSEARCH A/S (DK) | 2007-10-16 | — | — | US | disclosed |
| EP-1736468-A2 | Isatin derivatives with neurotrophic activity useful in the treatment of diseases mediated by the nerve growth factor (NGF) activation | NeuroSearch A/S (DK) | 2006-12-27 | — | — | EP | disclosed |
| US-20060229311-A1 | Isatine derivatives with neurotrophic activity | GROENBORG METTE | 2006-10-12 | — | — | US | disclosed |
| US-20030040518-A1 | Isatine derivatives with neurotrophic activity | ANIONA APS (DK) | 2003-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229311-A1 | Isatine derivatives with neurotrophic activity | BDNF, NTRK2, NGF | SMN1; SMN2 16/4885MAPK14 481/4885PPARG 3738/4885 |
| US-20030040518-A1 | Isatine derivatives with neurotrophic activity | BDNF, NTRK2, NGF | SMN1; SMN2 16/4885MAPK14 481/4885PPARG 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.